CCR4 and tropical spastic paraparesis: A monoclonal antibody against C‐C chemokine receptor type 4 (CCR4), which targets HTLV‐1‐infected cells, recently failed to show effectiveness in improving motor function in HAM/TSP patients, although transient reductions in HTLV‐1 PVL and inflammatory markers were demonstrated.25